KY-1044 (Alomfilimab; SAR 445256) is a fully humanized IgG1 monoclonal antibody that selectively targets the inducible costimulatory receptor (ICOS). This antibody is designed to deplete ICOS-high expressing cells through the mechanism of antibody-dependent cellular cytotoxicity (ADCC), facilitated by the engagement of FcγRIIIa receptors. Additionally, KY-1044 serves as a costimulatory molecule for cells expressing lower levels of ICOS, such as CD8+ effector T cells, via FcγR-dependent clustering. This dual functionality allows KY-1044 to modulate the differential expression of ICOS across various T-cell subtypes, thereby enhancing the intratumoral immune contexture and promoting an effective antitumor immune response. KY-1044 is primarily researched for its potential therapeutic applications in oncology, focusing on its ability to manipulate immune responses within the tumor microenvironment.
KY-1044 (Alomfilimab; SAR 445256) is a fully humanized IgG1 monoclonal antibody that selectively targets the inducible costimulatory receptor (ICOS). This antibody is designed to deplete ICOS-high expressing cells through the mechanism of antibody-dependent cellular cytotoxicity (ADCC), facilitated by the engagement of FcγRIIIa receptors. Additionally, KY-1044 serves as a costimulatory molecule for cells expressing lower levels of ICOS, such as CD8+ effector T cells, via FcγR-dependent clustering. This dual functionality allows KY-1044 to modulate the differential expression of ICOS across various T-cell subtypes, thereby enhancing the intratumoral immune contexture and promoting an effective antitumor immune response. KY-1044 is primarily researched for its potential therapeutic applications in oncology, focusing on its ability to manipulate immune responses within the tumor microenvironment.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
